E120 692
[6]
Chu KF, Rotker K, Ellsworth P. The impact of obesity on benign and malignant urologic conditions. Postgrad Med 2013;125:53–69.[7]
Amarenco G, Serikoff A, Chartier-Kastler E, et al. Metabolic syn- drome and urinary disorders. Prog Urol 2012;22:207–13.[8]
Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol 2016;13:108–19.[9]
Vignozzi L, Gacci M, Cellai I, et al. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflam- mation. Prostate 2013;73:789–800.[10]
Gacci M, Vignozzi L, Sebastianelli A, et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis 2013;16:101–6.
[11]
Vignozzi L, Morelli A, Corona G, et al. Testosterone protects the lower urinary tract from metabolic syndrome-induced alterations. Horm Mol Biol Clin Investig 2012;11:329–37.
[12]
Vignozzi L, Morelli A, Sarchielli E, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experi- mental study in rabbit. J Endocrinol 2012;212:71–84.
[13]
Rastrelli G, Corona G, Lotti F, et al. Flaccid penile acceleration as a marker of cardiovascular risk in men without classical risk factors. J Sex Med 2014;11:173–86.Mauro Gacci
a,
*
Linda Vignozzi
b
Giovanni Corona
c
Sergio Serni
a
Mario Maggi
b
a
Department of Urology, University of Florence, Careggi Hospital,
Florence, Italy
b
Andrology Unit, University of Florence, Careggi Hospital, Florence, Italy
c
Endocrinology Unit, Maggiore-Bellaria Hospital, Bologna, Italy
*Corresponding author. Department of Urology, University of Florence,
Viale A. Gramsci 7, Florence 50121, Italy. Tel. +39 3396640070.
E-mail address:
maurogacci@yahoo.it(M. Gacci).
October 13, 2016
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) e 1 1 9 – e 1 2 0
e120